Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:monoclonal_antibody
immunotherapy |
| gptkbp:administeredBy |
intravenous infusion
|
| gptkbp:approvalYear |
2016
|
| gptkbp:approvedBy |
gptkb:non-small_cell_lung_cancer
gptkb:urothelial_carcinoma gptkb:FDA gptkb:triple-negative_breast_cancer |
| gptkbp:ATCCode |
L01XC32
|
| gptkbp:brand |
gptkb:Tecentriq
|
| gptkbp:CASNumber |
gptkb:1448221-59-6
|
| gptkbp:developedBy |
gptkb:Genentech
gptkb:Roche |
| gptkbp:drugClass |
immunotherapy
|
| https://www.w3.org/2000/01/rdf-schema#label |
Atezolizumab
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:macromoleculeType |
gptkb:programmed_death-ligand_1
|
| gptkbp:mechanismOfAction |
immunotherapy
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
nausea
fatigue rash immune-related adverse events |
| gptkbp:target |
PD-L1
|
| gptkbp:UNII |
6X9OC3H4II
|
| gptkbp:usedFor |
gptkb:cancer
|
| gptkbp:bfsParent |
gptkb:Small_Cell_Lung_Cancer
|
| gptkbp:bfsLayer |
5
|